| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1372594 | Bioorganic & Medicinal Chemistry Letters | 2011 | 6 Pages |
Abstract
S1P1 receptor driven lymphopenia has proven utility in the treatment of an array of autoimmune disease states. As a part of our efforts to develop potent and selective S1P1 receptor agonists, we have identified a novel chemical series of 4-oxo-4-(5-(5-phenyl-1,2,4-oxadiazol-3-yl)indolin-1-yl)butanoic acid S1P1 receptor agonists.
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide
Keywords
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Daniel Buzard, Sangdon Han, Lars Thoresen, Jeanne Moody, Luis Lopez, Andrew Kawasaki, Thomas Schrader, Carleton Sage, Yinghong Gao, Jeff Edwards, Jeremy Barden, Jayant Thatte, Lixia Fu, Michelle Solomon, Ling Liu, Hussien Al-Shamma, Joel Gatlin, Minh Le,